To evaluate complications of different types of orbital implants following enucleation for retinoblastoma.
Introduction
Retinoblastoma is a rare malignant eye tumour arising from the retina in children. The tumour typically occurs in the first five years of life during retinal development and maturation. The incidence is estimated between 1 in 15.000 and 20.000 live births, accounting for approximately 10-15 new cases per year in the Netherlands. 1 A wide variety of globe saving modalities are available in the treatment of intraocular retinoblastoma: cryotherapy; transpupillary thermo therapy; intravenous chemotherapy (chemoreduction) with consolidation therapy; selective intra-arterial chemotherapy (SIAC); intravitreous chemotherapy; subconjunctival/ subtenon chemotherapy; plaque radiotherapy (brachytherapy), external beam radiation therapy (EBRT); or a combination of these. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Enucleation, however, remains an effective and often lifesaving treatment option especially in unilateral advanced intraocular retinoblastoma, which is seen most commonly.
Implant types and wrapping materials used in enucleation surgery have evolved over time. The orbital implant is inserted for the purpose of compensating orbital volume loss and as a substitute of an internal orbital growth stimulus, both resulting in improvement of cosmetic appearance. [12] [13] [14] The implant potentially facilitates movement of the prosthesis 12 and may reduce the risk of a contracted socket, which is especially seen in patients in whom enucleation is combined with EBRT. 15 Wrappings that envelop the solid and often rough surfaced implant devices are used for muscle attachment and prevention of conjunctival abrasion.
Complications after enucleation such as socket contraction, migration, exposure or extrusion of the implant, require revision surgery. This additional procedure can have a negative effect on the cosmetic outcome, such as contraction of the socket and fornices, decreased motility due to fibrosis and scarring and could have a negative influence on prosthesis fitting.
The present study aims to evaluate the complications that occurred during our 23 years of experience in enucleation procedures for retinoblastoma. Results are compared with the reviewed literature.
Methods

Patient population
A review of medical records revealed 216 patients with retinoblastoma treated with enucleation (8 bilateral) . In all cases, the diagnosis was histopathologically confirmed.
Results
Between April 1991 and June 2013, a total of 275 children (118 females, 157 males) were diagnosed with retinoblastoma in our institution. In this period, 224 eyes of 216 consecutive patients were enucleated (209 primary and 15 secondary enucleations). Mean age at surgery was 1.9 (median 1.5) years. The number of enucleated patients accounted for 78.6% of all patients diagnosed with retinoblastoma. Five patients were excluded: three died within one year, one moved abroad directly after surgery and one had exposure considered not implant-related. The patient characteristics are presented in Table 1 .
Recurrence and second primary malignancies
In one patient purulent discharge and exposure of the hydroxyapatite (HA) implant announced a local recurrence of retinoblastoma 7 months postenucleation. The patient was secondarily treated with local resection, chemotherapy, EBRT and implant replacement. This patient is still disease-free at 10.5 years of follow-up. As mentioned above this case is excluded since the exposure is not considered implant-related.
Two patients developed a second primary malignancy (both osteosarcoma, one in the fellow orbit, one located in the femur); both are still alive after extensive treatment.
Surgical materials and techniques
Over time different implant methods were used: no implant (n = 20), Allen implant (n = 18), scleral wrapped hydroxyapatite (n = 79), or acrylic implant (n = 102), see Figure 1 and Table 2 .
All enucleations are performed under general anesthesia. The basics of the procedure have remained consistent over time. We start by performing perilimbal dissection of conjunctiva and tenon, release of the oblique muscles, isolation of the four recti muscles (using vicryl sutures for later reattachment) and division of the optic nerve. In case of implant insertion the implant size is estimated using a dummy sizer. In case of Allen implants, the recti muscles are pulled through four openings and sutured in a central knot. With the hydroxyapatite implants, the muscles are pulled through a pre-cut hole in the banked donor sclera that covers the implant. With use of acrylic implants the recti muscles are attached (para)centrally to the enveloping banked donor sclera. Tenon and conjunctiva are always closed in two separate layers using soluble vicryl sutures. Finally, topical corticosteroid / antibiotic ointment is administered. Minor adaptations are shown in Table 2 . Postoperative treatment consists of a firm pressure bandage overnight and topical corticosteroid / antibiotic ointment b.i.d. for 7 days. Table 2 demonstrates the used techniques and implant material during enucleation.
Complications
Peroperative complications
A total of 21 peroperative complications were reported in 17 of the 219 surgeries (Table 3) .
Postoperative complications
With respect to the primary outcome parameters, the implant-related events Table 3 summarizes the complications per implant type. Successful strategies for repair included conjunctival closure (n = 6), sometimes repeatedly, placement of a scleral patch (n = 1) and watchful waiting (n = 3). Extrusion occurred in 6 patients, requiring implant explantation with or without replacement of the implant. Comparing the two most frequently inserted implant types, HA implants versus acrylic implants, the acrylic / sclera group had the tendency to expose or extrude less (5 of 102, 4.9%) compared to the HA / sclera group (10 of 79, 12.7%), X 2 (1, n = 181) = 3,52, df 1, p = 0.06. Regarding secondary outcome measures, 'socket contraction' was present only in patients who did not receive a primary implant. These patients were treated using socket reconstruction techniques such as fornix deepening sutures, mucosa-and fat transplants and bone pins to wear external prosthesis. However, the results of these repeated attempts were disappointing. 'Tilting' is a specific complication of the Allen implant occurring in 38.9% (7/18) . It causes improper prosthetic fit, conjunctival prolapse, and a decrease of implant motility. In 4 cases the implant was replaced. Table 4 ) suffered from persistent dysfunctioning of the levator muscle with a total ptosis as result. In one case the enucleation snare broke repeatedly with subsequent loss of the superior rectus muscle. The muscle was ultimately retrieved but this extra manipulation probably damaged the levator complex. In the other case the cause of the ptosis was unknown.
Additional treatment
In 78 cases (35.6%) additional chemotherapy and/or EBRT was administered for tumour treatment of the fellow eye or as a preventive measure if histopathological risk factors were present (Table 1) . Table 5 shows the frequency of occurrence of the complications 'extrusion' and 'exposure' of the implant related to additional therapy.
Additional treatment in the total group (including the cases without implant) significantly increased the risk of exposure, extrusion and contraction: 16.7% (13 of 78) versus 5.7% (8 of 141) (OR 3.3; 95% CI 1.3-8.4 p = 0.008). Considering the two most frequently used implants (HA and acrylic implants) as one group, the patients that were exposed to chemotherapy and/or EBRT (n = 66) demonstrated a 13.6% complication rate versus 5.2% in the non-exposed n = 115 group, p = 0.048. Of the previously mentioned complications, 70% occurred within the first year after surgery and approximately 50% within the first 6 months. Three years was the longest duration until exposure. Figure 2 shows the different complications in relation to implant type and additional treatment. Table 6 summarizes the 17 studies included for review [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] and the present study, each reporting the results of enucleation and implant insertion in children with retinoblastoma; the table shows the study period of these reports. A variety of implants ( Figure 3 ), combined with different types of wrappings, was used. We did not encounter any randomized controlled trials.
Review
Discussion
This retrospective study describes the surgical outcome of enucleation in retinoblastoma patients during the last 23 years in the Netherlands. It shows a shift over the years in the use of implant types. In the early years no implants were 
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inserted because of a general concern that recurrences could not be detected. This argument became less important with the advent of MRI. Since then, orbital implant insertion has become a routine procedure in our institution.
The first socket implants we used were Allen implants. Most complications were related to the design of the implant, where tilting resulted in a reversed effect of coupling to the ocular prosthesis. Since the early 1990s, the HA implant was frequently used. 
Im pl an t
Alle n (n = Table 6 . Overview of studies reporting results of enucleation and implant insertion in children with retinoblastoma Our results show that the HA implant accounts for more exposures compared to the solid acrylic implant, although extrusion rates were low in both groups. Our findings are in line with the American Academy report by Custer et al. 32 , which indicates that exposure rates of porous implants are similar to or higher than that reported for solid implants. . Vicryl mesh wrapped implants had a higher complication rate compared to polymer-coated implants (17.7% versus 9.3% exposure, respectively) (Kirzhner et al. 2013 ). Some wrapping materials do worse than a bare implant with exposure of 53% using mersilene wrapping (compared to 8% without wrapping) (Lee et al. 2000) , and 46% exposure with polyurethane wrapping compared to 5% with bare implant (Heimann et al. 2005 ). These reports seem to suggest that the type of wrapping plays an important role, where some wrapping materials with a potential inflammatory reaction seem unfavourable and increase exposure (Rosner et al. 1992) .
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In the present study, no side-effects were noted from the use of banked was strongly discouraged after the report of an incident in the UK in 1997, where both corneas and scleras from a donor, subsequently confirmed to have had sporadic CreutzfeldtJakob disease, were transplanted (Tullo et al. 2006) . Although no transmission of the disease has been reported thus far, this incident caused a shift to stricter donor selection criteria Overall, rates of extrusion in described studies were 0-2.2%. reported 3.0% extrusion in the t studied implant population. We assu that a discrepancy exists in the defini of extrusion. Some authors reported removal of the implant as managem of exposure, whereas in our practice necessity for explantation alone reported as extrusion.
To our knowledge, this report is largest study to evaluate the outco of orbital implants after enuclea for the treatment of retinoblastom which two subgroups (HA/sclera sus acrylic/sclera) are highly comp ble due to the use of the same proto and almost identical surgical t niques. However, the time lines a therefore, the follow-up duration fers between the two groups. In a tion, other implant types have not b compared and the contribution of artificial eye status (polished or improper fit) could not be tested in retrospective study. This emphas the need for future prospective stud
We conclude that primary orb implant insertion following enuclea for retinoblastoma is safe and is a ciated with low rates of complicati Insertion of an implant prevents so contraction, and additional retinob toma treatment is associated with increase in complication rate. Fina our study results suggest a favour outcome for scleral wrapped acr implants compared to the HA impl It was thought that the rough surface of the HA implant may induce tissue breakdown of the overlaying layers during eye movement. Also, orbital inflammatory responses to HA implants (characterized by a foreign body giant cell reaction) causing increased implant exposure have been documented. 33, 34 In contrast, Christmas et al. 16 reported a significantly higher rate of complications with acrylic spheres than other implants. Differences in surgical technique could explain this discrepancy: part unwrapped, and part without muscle reattachment. Medpor (porous polyethylene), currently the second most popular porous implant, was used in seven of the reviewed studies. Like the porous HA, Medpor showed considerable exposure rates of 21.6% 24 , 33% 26 and 61.5% 23 when implanted as a bare implant. As mentioned, porous implants require additional preventive measures to protect the conjunctiva from abrasion of the rough implant surface. Different measures for conjunctival protection are available: an implant may be wrapped by organic materials -which are either autologous (dermis-fat, fascia lata, temporalis fascia, posterior auricular muscle, rectus abdominis sheath) or allogenic (donor sclera, dura mater, bovine pericardium, dermis-fat)-or inorganic materials (polyglactin / vicryl mesh, polyglycolic acid mesh, polyurethane mesh, mersilene mesh, Gore-Tex), it may be anteriorly covered with a scleral patch or by insertion of a free orbital fat graft 22, 25, 26 , the implant may also have a prefabricated covering (the polymer-coated hydroxyapatite implant 35 ) or the implant itself can be adjusted with a smooth surface and predrilled tunnels for muscle attachment (Medpor SST   36 ). Promising results with the Medpor SST have been reported by Choi et al. 31 with no exposures in 44 retinoblastoma patients. The latter group is smaller than ours, but otherwise comparable with a substantial subgroup of patients (1/3) that also received additional therapy.
In our study both the acrylic and HA implants have a relative low complication rate. This might be attributed to the scleral wrapping technique that we use, which seems to reduce the risk of HA implant exposure 33, [37] [38] [39] and enables muscle reattachment in both the HA and acrylic group.
A low complication rate using scleral wrapping is supported by the studies of De Potter et al. 19 and Christmas et al. 16 reporting exposure rates of 3.3% and 1.0%. These rates are lower compared to our study, but this could be due to a difference in populations; theirs seem to have a considerably lower additional intervention rate (see Table 6 ). No comparable follow-up study with acrylic / sclera combination as a treatment in retinoblastoma is available.
The reported studies with no wrapping or other wrapping materials, had exposure rates ranging from 0% to 36.8%. 15, 17, 18, 21, 22, 28, 29 Vicryl mesh wrapped implants had a higher complication rate compared to polymer-coated implants (17.7% versus 9.3% exposure, respectively). 29 Some wrapping materials do worse than a bare implant with exposure of 53% using mersilene wrapping (compared to 8% without wrapping) 23 , and 46% exposure with polyurethane wrapping compared to 5% with bare implant. 28 These reports seem to suggest that the type of wrapping plays an important role, where some wrapping materials with a potential inflammatory reaction seem unfavourable and increase exposure. 34 In the present study no side-effects were noted from the use of banked donor sclera. The use of donor sclera was strongly discouraged after the report of an incident in the UK in 1997, where both corneas and scleras from a donor, subsequently confirmed to have had sporadic Creutzfeldt-Jakob disease, were transplanted. 40 Although no transmission of the disease has been reported thus far, this incident caused a shift to stricter donor selection criteria. 41 With proper donor screening and protocolled tissue handling, scleral transmission risks are very low. 42, 43 In our study, exposure to additional therapy resulted in an increased risk of complications. An increased exposure risk with additional therapy is also seen comparing the studies of Shildkrot et al. 15 and Kirzhner et al. 29 (20.7% versus 11.7%), reporting the same patient cohort but in Kirzhner et al. 29 with exclusion of adjuvant treated patients. Lee et al. 23 also described an increased risk, however, without statistical significance. In contrast, no harmful effect of additional therapy to implants was reported by Iordanidou et al. (n = 36) 25 and Choi et al. (n = 44) 31 , both using Medpor (SST) implants. Overall rates of extrusion in the described studies were 0-2.2%. We reported 3% extrusion in the total studied implant population. We assume that a discrepancy exists in the definition of extrusion. Some authors reported the removal of the implant as management of exposure, whereas in our practice the necessity for explantation alone was reported as extrusion.
To our knowledge, this report is the largest study to evaluate the outcome of orbital implants after enucleation for the treatment of retinoblastoma in which two subgroups (HA / sclera versus acrylic / sclera) are highly comparable due to the use of the same protocols and almost identical surgical techniques. However, the time lines and, therefore, the follow-up duration differs between the two groups. In addition, other implant types have not been compared and the contribution of the artificial eye status (polished or not, improper fit) could not be tested in this retrospective study. This emphasizes the need for future prospective studies.
We conclude that primary orbital implant insertion following enucleation for retinoblastoma is safe and is associated with low rates of complications. Insertion
